Bristol-Myers Squibb Co (NYSE:BMY) Shares Acquired by Neumann Capital Management LLC

Neumann Capital Management LLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 54.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,134 shares of the biopharmaceutical company’s stock after purchasing an additional 6,045 shares during the period. Neumann Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,100,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BMY. Garrett Wealth Advisory Group LLC bought a new stake in Bristol-Myers Squibb in the third quarter valued at about $26,000. Lenox Wealth Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 539 shares during the period. Financial Gravity Wealth Inc. boosted its holdings in shares of Bristol-Myers Squibb by 101.2% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 327 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Bristol-Myers Squibb by 52.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 230 shares during the period. Finally, Savior LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 83.35% of the company’s stock.

Shares of Bristol-Myers Squibb stock traded down $2.72 on Friday, hitting $64.16. The company had a trading volume of 16,360,601 shares, compared to its average volume of 12,153,140. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $68.34. The company has a market cap of $109.86 billion, a PE ratio of 18.49, a PEG ratio of 0.81 and a beta of 0.73. The business has a 50-day simple moving average of $64.02 and a 200-day simple moving average of $53.87. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same period in the prior year, the business earned $1.09 earnings per share. The business’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts predict that Bristol-Myers Squibb Co will post 4.34 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, January 2nd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s dividend payout ratio is 45.23%.

A number of brokerages recently issued reports on BMY. Mizuho assumed coverage on Bristol-Myers Squibb in a research note on Monday, November 25th. They set a “buy” rating for the company. Wolfe Research set a $66.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. Citigroup raised Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price objective on the stock in a report on Monday, January 6th. Gabelli began coverage on Bristol-Myers Squibb in a report on Wednesday, November 27th. They set a “buy” rating on the stock. Finally, Argus raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $61.69.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the sale, the insider now owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Growth Stocks

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.